Payment overview · 2025
General Payments
$214.91
10 reported records · 7 companies
Healthcare provider profile · identity verified
Jeffrey P Fraser, DO
Allopathic & Osteopathic Physicians|Family Medicine · VENICE, FL · NPI 1740292762
Verified facts
What the public records show
CMS Open Payments records show Jeffrey P Fraser, DO received $214.91 in general payments during 2025 across 10 reported records.
Novo Nordisk Inc accounted for 28.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Prolia by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $60.93 | 28.4% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $35.33 | 16.4% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $34.09 | 15.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $27.16 | 12.6% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $24.10 | 11.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $18.97 | 8.8% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $14.33 | 6.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $214.91 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $60.93 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $60.93 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $35.33 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $34.09 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $27.16 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $24.10 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $18.97 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $18.43 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $14.33 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $14.33 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 34 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
45 | 16 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
22 | 13 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
34 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 956 | 277 |
| Levothyroxine Sodium | Levothyroxine Sodium | 521 | 138 |
| Amlodipine Besylate | Amlodipine Besylate | 487 | 136 |
| Lisinopril | Lisinopril | 449 | 130 |
| Losartan Potassium | Losartan Potassium | 405 | 117 |
| Metoprolol Succinate | Metoprolol Succinate | 368 | 107 |
| Omeprazole | Omeprazole | 321 | 94 |
| Metformin Hcl | Metformin Hcl | 310 | 93 |
| Pantoprazole Sodium | Pantoprazole Sodium | 300 | 95 |
| Fluticasone Propionate | Fluticasone Propionate | 278 | 127 |
| Trazodone Hcl | Trazodone Hcl | 268 | 78 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 266 | 81 |
| Tamsulosin Hcl | Tamsulosin Hcl | 264 | 81 |
| Simvastatin | Simvastatin | 222 | 63 |
| Escitalopram Oxalate | Escitalopram Oxalate | 218 | 76 |
| Pravastatin Sodium | Pravastatin Sodium | 211 | 60 |
| Eliquis | Apixaban | 204 | 55 |
| Famotidine | Famotidine | 198 | 72 |
| Gabapentin | Gabapentin | 196 | 65 |
| Metoprolol Tartrate | Metoprolol Tartrate | 184 | 50 |
| Sertraline Hcl | Sertraline Hcl | 184 | 58 |
| Allopurinol | Allopurinol | 162 | 48 |
| Hydrochlorothiazide | Hydrochlorothiazide | 153 | 48 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 129 | 68 |
| Montelukast Sodium | Montelukast Sodium | 119 | 34 |
| Warfarin Sodium | Warfarin Sodium | 119 | 17 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 116 | 35 |
| Finasteride | Finasteride | 106 | 34 |
| Duloxetine Hcl | Duloxetine Hcl | 100 | 26 |
| Atenolol | Atenolol | 94 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 92 | 30 |
| Furosemide | Furosemide | 88 | 35 |
| Spironolactone | Spironolactone | 87 | 29 |
| Alendronate Sodium | Alendronate Sodium | 86 | 26 |
| Carvedilol | Carvedilol | 79 | 25 |
| Pioglitazone Hcl | Pioglitazone Hcl | 78 | 25 |
| Alprazolam | Alprazolam | 72 | 28 |
| Potassium Chloride | Potassium Chloride | 71 | 25 |
| Mirtazapine | Mirtazapine | 69 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 68 | 20 |
| Bupropion Xl | Bupropion Hcl | 62 | 22 |
| Estradiol | Estradiol | 62 | 21 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 62 | 55 |
| Meloxicam | Meloxicam | 58 | 29 |
| Donepezil Hcl | Donepezil Hcl | 56 | 17 |
| Glimepiride | Glimepiride | 54 | 17 |
| Doxycycline Hyclate | Doxycycline Hyclate | 51 | 47 |
| Ipratropium Bromide | Ipratropium Bromide | 50 | 36 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 50 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 50 | 17 |
| Ketoconazole | Ketoconazole | 49 | 28 |
| Xarelto | Rivaroxaban | 48 | 14 |
| Buspirone Hcl | Buspirone Hcl | 47 | 18 |
| Lovastatin | Lovastatin | 47 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 47 | 28 |
| Prednisone | Prednisone | 46 | 31 |
| Synthroid | Levothyroxine Sodium | 45 | 16 |
| Enalapril Maleate | Enalapril Maleate | 42 | 14 |
| Methylprednisolone | Methylprednisolone | 42 | 40 |
| Cephalexin | Cephalexin | 41 | 35 |
| Myrbetriq | Mirabegron | 39 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 39 | 17 |
| Ezetimibe | Ezetimibe | 38 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 37 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 36 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 35 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 34 | 12 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 31 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 31 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 31 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 30 | suppressed |
| Jardiance | Empagliflozin | 30 | suppressed |
| Azithromycin | Azithromycin | 29 | 22 |
| Celecoxib | Celecoxib | 28 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 28 | 19 |
| Valsartan | Valsartan | 28 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 27 | suppressed |
| Januvia | Sitagliptin Phosphate | 27 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 27 | suppressed |
| Naproxen | Naproxen | 27 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 27 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 26 | suppressed |
| Ozempic | Semaglutide | 25 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 24 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 24 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 24 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 23 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 23 | 14 |
| Ventolin Hfa | Albuterol Sulfate | 23 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Irbesartan | Irbesartan | 22 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Nitroglycerin | Nitroglycerin | 22 | 13 |
| Prolia | Denosumab | 22 | 13 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Lorazepam | Lorazepam | 21 | 14 |
| Amoxicillin | Amoxicillin | 20 | 16 |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 19 | suppressed |
| Temazepam | Temazepam | 19 | suppressed |
| Cefdinir | Cefdinir | 18 | 14 |
| Clonazepam | Clonazepam | 18 | suppressed |
| Digoxin | Digoxin | 18 | suppressed |
| Mupirocin | Mupirocin | 18 | 16 |
| Ramipril | Ramipril | 18 | suppressed |
| Sucralfate | Sucralfate | 18 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Bumetanide | Bumetanide | 17 | suppressed |
| Nystatin | Nystatin | 17 | suppressed |
| Primidone | Primidone | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Diazepam | Diazepam | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Pioglitazone-Metformin | Pioglitazone Hcl/Metformin Hcl | 16 | suppressed |
| Trulicity | Dulaglutide | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 15 | suppressed |
| Torsemide | Torsemide | 15 | suppressed |
| Jantoven | Warfarin Sodium | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Tradjenta | Linagliptin | 14 | suppressed |
| Clonidine | Clonidine | 13 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 12 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 12 | 12 |
| Telmisartan | Telmisartan | 12 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Fluocinolone Acetonide Oil | Fluocinolone Acetonide Oil | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $214.91 · 10 records | Novo Nordisk Inc | CAPVAXIVE, GARDASIL 9, JARDIANCE, OTEZLA, Ozempic, REPATHA, Rybelsus, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error